TNF inhibitor

      Rheumatology Roundup
      1 year 7 months ago
      Rheumatology,Roundup,2023
      Rheumatology Roundup - ACR 2023
      1 year 7 months ago
      Drs. Jack Cush and Arthur Kavanaugh discuss highlights and key takeaways from ACR 23.
      TNFi and cardiovascular disease in AxSpA
      1 year 7 months ago
      SpaA Updates: Anti-infliximab Antibodies, Difficult to Treat AxSpa
      1 year 7 months ago
      Impressive and important study supporting safety of TNF inhibitors among patients with RA-ILD. Elegant methods of target

      Jeffrey Sparks MD MMSc jeffsparks

      1 year 7 months ago
      Impressive and important study supporting safety of TNF inhibitors among patients with RA-ILD. Elegant methods of target trial emulation. Congrats to the authors on plenary presentation! #ACR23 https://t.co/P7keAoOX7M
      Switching or Discontinuing Biologics in Psoriatic Arthritis
      1 year 7 months ago
      rare
      Here at Last: Treatment Options for VEXAS
      1 year 7 months ago
      We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for nearly 3 years, but there has been relatively little to say about how to treat it. To date there have been over twice as many publications about VEXAS (263 publications) as there have been patients described with respect to treatment strategies (116 patients). One of the late breaking abstracts may finally have rectified this imbalance.
      EXXELERATE Study: Do High RF Titers Impact Response to TNF Inhibitors?
      1 year 7 months ago
      After 3 years, 25% (95% CI: 13 to 38) remained flare-free in the tapering TNFi group compared to 85% (70 to 93) in the s

      Dr. Antoni Chan

      1 year 7 months ago
      After 3 years, 25% (95% CI: 13 to 38) remained flare-free in the tapering TNFi group compared to 85% (70 to 93) in the stable TNFi group, hazard ratio for flare of 9.4 (3.9 to 22.8), ARCTIC REWIND, Kjorholt K, LB Abst#L07 #ACR23 #ACRBest @RheumNow https://t.co/fqxfU3jE0q https://t.co/J0qBeKNsEW
      Treatments in SpA
      1 year 7 months ago
      Anterior uveitis incidence across different axSpA treatments
      Large review and meta-analysis on TNFi, IL-17i, JAKi

      Immu

      Robert B Chao, MD

      1 year 7 months ago
      Anterior uveitis incidence across different axSpA treatments Large review and meta-analysis on TNFi, IL-17i, JAKi Immunomodulatory therapy protective against uveitis flare Greatest in TNFi and JAKi @RheumNow #ACR23 Abs# 2550 https://t.co/l3BTL3GuRt
      Simulated Trials to Counter ORAL Survelliance
      1 year 7 months ago
      #ACR23 Abs #L07 data do not support tapering of TNFi treatment among RA patients in sustained remission in 3 year study.

      Dr. Rachel Tate

      1 year 7 months ago
      #ACR23 Abs #L07 data do not support tapering of TNFi treatment among RA patients in sustained remission in 3 year study. https://t.co/d0ZBWDKZlB https://t.co/EdllyGUT1y
      Persistence of IL-17i vs. TNFi in PsA treatment

      Large database study
      Persistence of IL-17i slightly greater than TNFi

      Robert B Chao, MD

      1 year 7 months ago
      Persistence of IL-17i vs. TNFi in PsA treatment Large database study Persistence of IL-17i slightly greater than TNFi over 12 months Are IL-17i a better longterm strategy for PsA pts? @RheumNow #ACR23 Abs# 2240 https://t.co/9km5XgXcLE
      Baker et al. TNFi vs triple therapy by BMI. 907 patients from TEAR/RACAT. Those under/normal weight have a better respon

      Richard Conway

      1 year 7 months ago
      Baker et al. TNFi vs triple therapy by BMI. 907 patients from TEAR/RACAT. Those under/normal weight have a better response to TNFi, overweight/obese respond equally to both. Abstr#2541 #ACR23 @RheumNow https://t.co/SROD3esMCD https://t.co/ni3I8tD7wI

      Catch up on Conference Podcasts

      ×